Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Zoom
ZM
|
+$1.14B |
| 2 |
AbbVie
ABBV
|
+$537M |
| 3 |
T-Mobile US
TMUS
|
+$504M |
| 4 |
Baidu
BIDU
|
+$474M |
| 5 |
Kroger
KR
|
+$448M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.32B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$504M |
| 5 |
Humana
HUM
|
+$466M |
Sector Composition
| 1 | Healthcare | 23.45% |
| 2 | Technology | 16.11% |
| 3 | Consumer Staples | 10.59% |
| 4 | Consumer Discretionary | 9.95% |
| 5 | Communication Services | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3176
Solitario Resources
XPL
$70.5M
| $189K | ﹤0.01% |
600,416
+183,386
| +44% | +$57.7K |
|
3177
HBT Financial
HBT
$818M
| $188K | ﹤0.01% |
+14,100
| New | +$188K |
|
3178
Peraso
PRSO
$7.66M
| $188K | ﹤0.01% |
2,569
-43
| -2% | -$3.15K |
|
3179
REV Group
REVG
$3.12B
| $188K | ﹤0.01% |
30,800
-7,991
| -21% | -$48.8K |
|
3180
KALA BIO
KALA
$119M
| $181K | ﹤0.01% |
344
-1,988
| -85% | -$1.05M |
|
3181
ClearPoint Neuro
CLPT
$315M
| $180K | ﹤0.01% |
50,600
+22,300
| +79% | +$79.3K |
|
3182
Exicure
XCUR
$22.7M
| $179K | ﹤0.01% |
490
-1,266
| -72% | -$462K |
|
3183
Plus Therapeutics
PSTV
$46.6M
| $178K | ﹤0.01% |
5,597
+194
| +4% | +$6.17K |
|
|
HZN
3184
DELISTED
Horizon Global Corporation
HZN
| $178K | ﹤0.01% |
81,002
-1,900
| -2% | -$4.18K |
|
|
SSY
3185
DELISTED
SunLink Health Systems
SSY
| $177K | ﹤0.01% |
197,800
+30,400
| +18% | +$27.2K |
|
3186
Xenetic Biosciences
XBIO
$4.78M
| $177K | ﹤0.01% |
17,320
+908
| +6% | +$9.28K |
|
|
IMMP
3187
Immutep
IMMP
$244M
| $176K | ﹤0.01% |
162,639
-174,650
| -52% | -$189K |
|
3188
Oblong
OBLG
$6.63M
| $176K | ﹤0.01% |
197
+67
| +52% | +$59.9K |
|
|
EVLO
3189
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $176K | ﹤0.01% |
1,799
+420
| +30% | +$41.1K |
|
3190
Oragenics
OGEN
$4.75M
| $174K | ﹤0.01% |
+139
| New | +$174K |
|
|
OSN
3191
DELISTED
Ossen Innovation Co., Ltd.
OSN
| $173K | ﹤0.01% |
61,589
-15,317
| -20% | -$43K |
|
|
ASXC
3192
DELISTED
Asensus Surgical, Inc.
ASXC
| $172K | ﹤0.01% |
+318,467
| New | +$172K |
|
|
VVUS
3193
DELISTED
Vivus Inc
VVUS
| $169K | ﹤0.01% |
205,341
-211,804
| -51% | -$174K |
|
|
CRESY
3194
Cresud
CRESY
$537M
| $168K | ﹤0.01% |
+58,511
| New | +$168K |
|
3195
Alaunos Therapeutics
TCRT
$5.25M
| $167K | ﹤0.01% |
338
-4,176
| -93% | -$2.06M |
|
|
IRS
3196
IRSA Inversiones y Representaciones
IRS
$958M
| $166K | ﹤0.01% |
+53,025
| New | +$166K |
|
|
BKYI
3197
BIO-key International
BKYI
$5.18M
| $164K | ﹤0.01% |
+1,283
| New | +$164K |
|
|
BCOM
3198
DELISTED
B Communications Ltd
BCOM
| $164K | ﹤0.01% |
82,466
+14,450
| +21% | +$28.7K |
|
3199
Phio Pharmaceuticals
PHIO
$13.3M
| $162K | ﹤0.01% |
687
+306
| +80% | +$72.2K |
|
|
THER
3200
DELISTED
THERATECHNOLOGIES INC COM
THER
| $161K | ﹤0.01% |
80,300
+29,300
| +57% | +$58.7K |
|